The market is expected to be rangebound with a positive bias. Below are some short-term trading ideas to consider.
Prabhudas Lilladher is bullish on JB Chemicals and Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2030 in its research report dated July 31, 2025.
Stocks to Watch, 31 July: Stocks like Tata Steel, Aurobindo Pharma, Gujarat Gas, Navin Fluorine International, Hitachi Energy, Sagility India, InterGlobe Aviation, Mahindra and Mahindra, Brigade Hotel Ventures, and Jio Financial Services will be in focus on July 31.
Stocks to Watch, 30 June: Stocks like Torrent Pharmaceuticals, JB Chemicals and Pharmaceuticals, Jyoti CNC Automation, BHEL, Alembic Pharma, Waaree Energies, Prestige Estates Projects, Bharti Airtel, Le Lavoir, Reliance Industries, and Hind Rectifiers will be in focus on June 30.
Stocks to watch, 25 June: Stocks like BLS E-Services, JB Chemicals and Pharmaceuticals, Aurobindo Pharma, Timex Group India, Infosys, Hindalco Industries, Bajel Projects, Arisinfra Solutions, RITES, and PTC Industries will be in focus on June 25.
Prabhudas Lilladher is bullish on JB Chemicals and Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2030 in its research report dated May 16, 2025.
Stocks to Watch, Mar 27: Stocks like TVS Supply Chain Solutions, Timken India, Indian Hotels Company, Restaurant Brands Asia, IRM Energy, Ashok Leyland, Vedanta, NHPC, MSTC, Bank of India, Aditya Birla Capital, Macrotech Developers, Bandhan Bank, HDFC Bank, Hindustan Unilever, and Oracle Financial Services Software will be in focus on March 27.
The benchmark indices remain bullish despite Tuesday's consolidation and are expected to move northward in the upcoming sessions. Below are some trading ideas for the near term.
Prabhudas Lilladher is bullish on JB Chemicals and Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 2075 in its research report dated February 06, 2025.
Revenue from operations came in at Rs 861.7 crore, up 13 percent from Rs 762 crore in the year-ago quarter.
Currently, the market landscape is defined by the 20,900–21,600 range.
The 33 drugs includes two each from JB Chemicals and Pharmaceuticals, Eris Lifesciences, Zydus Healthcare, Cipla, Sun Pharmaceutical, and Sanofi India and one from Torrent Pharma.